Sio Gene Therapies Inc. (SIOX) Financial Statements
Sio Gene Therapies Inc. (SIOX) files with the U.S. Securities and Exchange Commission under CIK 0001636050. 10KGenie shows its annual and quarterly statements from SEC filings.
Key Figures, Fiscal Year 2022
- Net Income
- -$71.90 million
- Total Assets
- $75.08 million
- Net Cash from Operations
- -$60.35 million
Fiscal year ended Mar 31, 2022. Latest periodic SEC filing: Feb 14, 2023. Source: SEC filings (EDGAR XBRL).
Open the full financial statements for SIOX in 10KGenie
Data from SEC EDGAR filings. 10KGenie is not affiliated with the SEC. SEC Filing History